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Background: Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several
Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants
spectrum of patients with suspected LS in Latin America.
Methods: Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated
families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant
colorectal (CRC) inheritance syndrome.
Results: We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic
testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of
pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM
up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private
and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%,
respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international
founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported,
thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to
identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are
still the primary methods in several countries where no genetic testing for LS is available yet.
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Conclusion: The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered
genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic
testing and counseling in all of Latin America countries.
Keywords: Lynch syndrome, Mmr, Latin America, Variants,Background
LS is caused by a defective mismatch repair (MMR) sys-
tem, due to the presence of germline defects in at least
one of the MMR genes, MLH1, MSH2, MSH6, PMS2, or
to deletions of the 3′ portion of the EPCAM gene [1].
Such variants are here referred to as path_MMR and,
when specifying one of the genes, as path_MLH1,
path_MSH2, path_MSH6, path_PMS2 or path_EPCAM
[2, 3]. LS is clinically classified according to the
Amsterdam (AMS) criteria and/or the Bethesda guide-
lines, both relying in clinical information and family his-
tory. The Bethesda guidelines also takes into account the
microsatellite instability (MSI) tumor marker, which is a
signature characteristic of MMR-deficient tumors [4–7].
MSI or immuno-histochemical (IHC) testing of tumors
are strategies to select patients for subsequent germline
diagnostic testing in blood [8].
LS patients have an increased lifetime risk of colorectal
cancer (CRC) (70–80%), endometrial cancer (50–60%),
stomach cancer (13–19%), ovarian cancer (9–14%), can-
cer of the small intestine, the biliary tract, brain as well
as carcinoma of the ureters and renal pelvis [9]. The cu-
mulative incidence of any cancer at 70 years of age is
72% for path_MLH1 and path_MSH2 carriers but lower
in path_MSH6 (52%) and path_PMS2 (18%) carriers.
Path_MSH6 and path_PMS2 carriers do not have an
increased risk for cancer before 40 years of age [2, 3].
The identification of LS patients is a goal because an
early diagnosis and intensive screening may predict the
disease and/or improve the disease prognosis [2].
The path_MMR variant spectrum of LS has been
widely studied in CRC patients from North America,
Europe, Australia and Asia. In the past decade, signifi-
cant advances have been made in molecular testing and
genetic counseling for LS in several Latin America
countries [10–51].
A broad definition of Latin America is that all countries
of the Americas south of the United States are included,
with Mexico, Cuba, Puerto Rico and all the countries
located in South America as well as the Caribbean Islands.
Latin America presents with genetically somewhat diffe-
rent populations, where European and African immigrants
have a concentration of the Caucasian population in the
southern regions of the continent, whereas in the northern
region, the population is predominantly Mestizo (a mixture
of European and Amerindian) [52].Among LS patients, the prevalence of path_MLH1 is
42%, path_MSH2 is 33%, path_MSH6 is 18% and
path_PMS2 is 8% [53]. However, recent studies in Latin
America LS families described the predominance of
path_MSH2 (46%- 66%), followed by path_MLH1 (25%–
43%), path_MSH6 (7%–8%), path_PMS2 (2%) and
path_EPCAM (2%) [32, 36, 47]. Some Latin America LS
variant spectrum included variants that have not previ-
ously been reported and potential founder effects which
are useful for future development of genetic testing in
these populations. It enables the comparison of LS char-
acteristics and MMR variants across genetic ancestry
background differences among these populations [12, 20,
23, 26, 32, 36, 40].
The clinical, molecular and MMR variant spectrum of
LS has not been fully studied in all Latin America coun-
tries. Our study aims to combine both unpublished
register data and published data in order to better de-
scribe the LS molecular profile and to update the previ-
ously described South American path_MMR variant
spectrum study [32].
Methods
Unpublished data from hereditary cancer registries and
published data from patients with suspected LS from
Latin America have been included in this work. Through
research collaborations, data from the Latin America
hereditary cancer registers are available following direct
contact with the register. The data include results from
germline DNA testing, tumor testing (based on MSI
analysis and/or IHC) and family history (Fig. 1).
Hereditary cancer registries
Families that fulfilled the AMSII criteria [4, 5], the Be-
thesda guidelines [6] and/or other criteria i.e. families
suggestive of a dominant CRC inheritance syndrome
were selected from 11 hereditary cancer registries from
8 countries: Hospital Italiano (Buenos Aires, Argentina),
Hospital Español de Rosario (Rosario, Argentina), Hos-
pital Privado Universitario de Cordoba (Cordoba,
Argentina), Centro de Enfermedades Neoplasicas
Oncovida (La Paz, Bolivia), Barretos Cancer Hospital
(Barretos, Brazil), Hospital de Clinicas de Porto Alegre
(Rio Grande do Sul, Brazil), Clinica Las Condes
(Santiago, Chile), Clinica del Country (Bogota,
Colombia), Instituto Nacional de Cancerologia (Mexico
Fig. 1 Flowchart depicting the groups of patients with suspected LS in Latin America included in the study. We included unpublished register
data and published data from germline MMR testing, tumor testing and family history
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plasicas (Lima, Peru) and Hospital de las Fuerzas Ar-
madas (Montevideo, Uruguay).
Patients were informed about their inclusion into the
registries, which generally contained data on family his-
tory, clinical information, age at onset and results of
DNA testing or tumor screening in the diagnosis of LS.
Written informed consent was obtained from all partici-
pants during genetic counseling sessions.
LS databases
A systematic review was performed in order to identify
published reports on MMR variants in LS or hereditary
CRC by querying the PubMed, SciELO and Google data-
bases using specific key words (focusing on clinical,
tumor or genetic testing information associated with the
MMR genes) and taking into account publications in
three languages, namely Spanish, English and Portu-
guese, up to July 2016. The search terms were “Lynch
syndrome”, “hereditary colorectal cancer”, “hereditary
colorectal cancer and Latin America” and “Lynch syn-
drome and Latin America”. We also used keywords in
association with the names of Latin America countries
(e.g., “Lynch syndrome and Colombia”). The results of
the search were subsequently screened for the presence
of path_MMR variants or tumor screening, clinical diag-
nosis and family history.
We found 34 LS reports from 12 countries including
Argentina [10, 14, 17, 18], Brazil [11, 15, 19, 22, 25, 28,
29, 37, 38, 43], Chile [20, 31], Colombia [12, 16, 23, 48],
Mexico [27, 44, 49, 51], El Salvador and Guatemala [51],
Paraguay [50], Peru [24, 33, 35, 45], Puerto Rico andDominican Republic [21, 36], South America [26, 32, 47]
and Uruguay [13].
Germline DNA testing
Genetic testing was generally based on Sanger sequen-
cing of MLH1, MSH2, MSH6 and/or PMS2 and/or
EPCAM in 7 participating centers from Argentina (Hos-
pital Italiano de Buenos Aires and Hospital Español de
Rosario), Brazil (Barretos Cancer Hospital and Hospital
de Clinicas de Porto Alegre), Chile (Clinica Las Condes),
Colombia (Clinica del Country) and Uruguay (Hospital
de Las Fuerzas Armadas). Multiplex Ligation-dependent
Probe Amplification (MLPA) was used to analyze gen-
omic rearrangements in MMR and EPCAM genes
(SALSA kit P003, MRC-Holland, Amsterdam, Nether-
land). For PMS2 analysis, especially for exons 12 to 15,
to ensure the correct analysis of PMS2 and to avoid
pseudogene co-amplification, a long-range PCR followed
by a nested PCRs strategy was adopted. After amplifica-
tion, sequencing was performed according to the manu-
facturer’s instructions.
In addition, we took into consideration the results of
germline DNA testing described in 15 previously pub-
lished LS reports [10, 13, 17, 18, 20, 23, 26, 31, 32, 36,
37, 44, 47, 48, 51].
Tumor testing
Methods to assess tumor MMR status, e.g. MSI analysis
and/or MMR protein staining are being currently used
in Cordoba (Argentina), Lima (Peru), La Paz (Bolivia)
and Mexico City (Mexico) as an approach to identify po-
tential carriers of germline path_MMR variants.
Rossi et al. BMC Cancer  (2017) 17:623 Page 4 of 26Germline MMR testing is then mandatory to confirm LS
cases.
Families from Peru (Instituto Nacional de Enferme-
dades Neoplasicas) were evaluated for MSI using a 5-
mononucleotide marker panel (BAT-25, BAT-26,
D2S123, D17S250 and D5S346). Tumors were classified
into three categories and defined as MSI high (MSI-H)
when ≥2 markers were unstable, MSI low (MSI-L) when
one marker was unstable and microsatellite stable (MSS)
when none of the markers were unstable. In Bolivia
(Centro de Enfermedades Neoplasicas Oncovida), MSI
analysis was evaluated by 1-mononucleotide marker
panel (BAT-26).
IHC analysis for MMR protein expression was per-
formed on paraffin-embedded tumor tissue sections, as
previously described [32]. In Argentina (Hospital Privado
Universitario de Cordoba), Mexico (Instituto Nacional
de Cancerologia) and Peru, IHC was evaluated using 4-
MMR proteins (MLH1, PMS2, MSH2 and MSH6).
Besides the information directly retrieved from these
participating centers, we also collected MSI and/or IHC
data from 15 LS published reports [14–16, 18, 21, 22,
24, 25, 27, 28, 31, 35, 38, 43, 45].Family history
Available data of family history of patients with CRC in-
cluded 4 published reports from Brazil [19], Mexico
[49], Paraguay [50] and Peru [33].MMR variants nomenclature and classification
The nomenclature guidelines of the Human Genome
Variation Society (HGVS) were used to describe the de-
tected MMR variants [54]. Variants were described by
taking into account the following reference sequences:
NM_000249.2 (MLH1), NM_000251.2 (MSH2),
NM_000179.2 (MSH6), and NM_001322014.1 (PMS2).
The recurrence or novelty of the identified variants was
established by interrogating four databases (in their lat-
est releases as of August 2016): the International Society
of Gastrointestinal Hereditary Tumors (InSIGHT) data-
base (accessed via the Leiden Open Variation Database/
LOVD), the Universal Mutation Database (UMD), Clin-
Var, and the Human Gene Mutation Database (HGMD).
The MMR variants were classified according to the 5-
tier classification system into the following categories:
class 5 (pathogenic), class 4 (likely pathogenic), class 3
(uncertain variants), class 2 (likely not pathogenic) and
class 1 (not pathogenic) [55]. Novel MMR variants were
considered class 5 if they: a) introduced a premature
stop codon in the protein sequence (nonsense or frame-
shift); b) occurred at the most conserved positions of
donor or acceptor splice sites (i.e. IVS ± 1, IVS ± 2); or
c) represented whole-exon deletions or duplications.Well established polymorphisms, Class 1 variants and
Class 2 variants were considered normal variants and
not included in this study, except for the MSH6
c.733A > T, which has conflicting interpretations of
pathogenicity. We focused on Class 3, Class 4 and Class
5 variants in this study.
In addition, we updated our previous South American
LS study [32] according to the 5-tier classification sys-
tem, with InSiGHT updates [55].
Splicing-dedicated bioinformatics analysis
The potential impact on RNA splicing induced by the
MMR variants was evaluated by focusing on alterations
of donor and acceptor splice sites. We took into consid-
eration both the potential impairment of reference splice
sites and the possibility of creation of de novo splice
sites. The analysis was performed by using the MaxEntS-
can algorithm [56] interrogated by using the Alamut
software (Interactive Biosoftware, France) [57, 58]. For
stratification purposes, negative alterations of reference
splice sites were deemed important when MaxEntScan
scores showed ≥15% decrease relative to corresponding
wild-type splice sites [57]. The possibility of variant-
induced de novo splice sites was assessed by annotating
all increments in local MaxEntScan scores and compar-
ing their values with those of reference splice sites as
well as of nearby cryptic splice sites. In this case and for
exonic variants, only scores equal or higher to those of
the corresponding reference splice site within the same
exon (as well as of local cryptic sites) were considered
worth noting. In the case of intronic variants, only
scores equal or higher to those of the weakest corre-
sponding reference splice site within the same gene (as
well as of local cryptic splice sites) were considered as
potentially creating de novo splice sites.
Statistical analysis
Clinical characteristics were described using frequency
distributions for categorical variables and summary mea-
sures for quantitative variables. To assess comparability
of study groups, chi-square test or Fisher’s exact test was
used for categorical variables and Student’s t test or
Mann-Whitney to compare quantitative variables.
The statistical analyses were performed using the stat-
istical software package IBM SPSS Statistics 20 (SPSS©,
Chicago, IL, USA) and STATA 12© (StataCorp. 2011.




By combining data provided by 7 participating centers,
we identified suspected LS in a total of 881 Latin Amer-
ica individuals belonging to 344 unrelated families
Rossi et al. BMC Cancer  (2017) 17:623 Page 5 of 26(Table 1, Fig. 1). Path_MMR genes were identified in
47% (range 39–64% depending on the participating
countries/registries) of the families that fulfilled the
AMSII criteria and/or the Bethesda guidelines and/or
other criteria (Table 1). When the AMSII criteria were
considered, the path_MMR genes detection raised to
64% (91/142), whereas 32% (54/170) and 23% (11/47)
fulfilled the Bethesda guidelines and other criteria, re-
spectively. The range of the mean age at diagnosis was
32–45 years for CRC and 43–51 years for endometrial
cancer depending on the countries/registries (Table 1).
Of the 410 path_MMR carriers, MLH1 was affected in
53.9% (221/410) of the cases, MSH2 in 32.4% (133/410),
MSH6 in 9.5% (39/410), PMS2 in 3.4% (14/410) and
EPCAM in 0.8% (3/410) (Table 1).
Fifteen published data from Argentina, Brazil, Chile,
Colombia, Dominican Republic, El Salvador, Guatemala,
Mexico, Puerto Rico, South America and Uruguay con-
tained information about 962 tested individuals belong-
ing to 1514 suspected LS families (Table 2, Fig. 1).
Path_MMR variants were identified in 40% (389/962)
(range 25–100% in the different databases/countries) of
the families that fulfilled the AMSII criteria and/or the
Bethesda guidelines and/or other criteria. The range of
the mean age at diagnosis was 35–45 years for CRC and
41–49 years for endometrial cancer in the different data-
bases (Table 2). Of the 389 path_MMR carriers, MLH1
was affected in 52.4% (204/389), MSH2 in 42.7% (166/
389), MSH6 in 3.6% (14/389), PMS2 in 0.8% (3/389) and
EPCAM in 0.5% (2/389) (Table 2).
Latin America MMR variants
In total, 220 unique alterations were identified, including
71 frameshift variants, 50 missense variants, 40 nonsense
variants, 36 intronic variants and 23 large deletions/dupli-
cations. Frameshift and missense variants were the most
common alterations (32% and 23%, respectively), followed
by nonsense variants (18%), intronic variants (16%) and
large deletions/duplications (11%) (Fig. 2, Table 3).
By the MaxEntScan algorithm, we found that 12% of
the variants in our cohort are expected to have a nega-
tive impact on RNA splicing (Table 3). Indeed, for 27
out of the 220 variants, the MaxEntScan algorithm pre-
dicts a significant decrease in splice site strength (>15%
decrease in MaxEntScan scores relative to corresponding
wild-type splice sites). These include 23 intronic variants
(7 within acceptor sites and 16 at donor sites) and 4 ex-
onic variants (located either at the penultimate or at the
last position of the exon). Among these variants, 24 are
already considered pathogenic (either Class 4 or Class 5,
with MaxEntScan scores ranging from −23% to −100%
of WT), including 15 variants located at the most con-
served positions of the consensus splice sites, i.e. IVS ± 1
or IVS ± 2, and a nonsense mutation located at thepenultimate position of MLH1 exon 8. The three-
remaining potential splicing mutations are either cur-
rently considered as Class 3 (MLH1 c.588G + 5G > C,
and PMS2 c.1144G > C) or have not yet been reported
(MLH1 c.588 + 5G > T). Further studies will be neces-
sary to determine if these three variants cause splicing
alterations as predicted by MaxEntScan (decrease in
donor splice site strength, MaxEntScan scores ranging
from −27% to −55% of WT), and if they are pathogenic
or not.
Our in-silico assessment of potential variant-induced
de novo splice sites (data not shown) indicates that 3
out of the 220 variants analyzed in this study are likely
to create new splice sites. More precisely, MLH1 c.117-
1G > T is predicted to destroy the acceptor site of
MLH1 exon 2 and to concomitantly create a potential
new and stronger acceptor site 5 nucleotides down-
stream, within the exon;MSH2 c.645 + 1_645 + 10delins15
is expected to destroy the donor site of MSH2 exon 3
and to create a new donor site 14 nucleotides down-
stream the reference site, within intron 8; and PMS2
c.804-1G > T is predicted to destroy the acceptor site of
PMS2 exon 8 and to concurrently create a new and
stronger acceptor site, 8 nucleotides downstream, within
the exon. These in silico predictions support the classifi-
cation of MLH1 c.117-1G > T, MSH2
c.645 + 1_645 + 10delins15 and PMS2 c.804-1G > T as
pathogenic (Table 3).
Though the single nucleotide variants (SNV) were
spread over the genes, most frequently affected regions
included exons 11 of MLH1 (15%), exon 3 and 7 of
MSH2 (17 and 15%), exon 4 of MSH6 (65%) and exons
11 and 13 of PMS2 (31% and 23%).
We found that the Latin America LS variant spectrum
was broad with 80% (175/220) alterations being private
i.e., observed in a single family, 15% (33/220) observed in
2–3 families and 6% (12/220) variants observed in ≥4 fam-
ilies. Forty-one variants (19%) had not previously been re-
ported in LS, and thus herein represent novel genetic
variants in the MMR genes (including 10 in MLH1, 13 in
MSH2, 11 in MSH6, 5 in PMS2 and 2 in EPCAM). The
classification of the remaining 179 variants is indicated in
Table 3, 37 variants being currently considered as Class 3,
10 as Class 4, 131 as Class 5 and 1 has conflicting inter-
pretations of pathogenicity (Table 3, Fig. 3). The variants
have been submitted to the InSiGHT locus-specific data-
base (https://www.insight-group.org).
In total, 45 MMR variants identified in at least two
families were classified as recurrent. Among these, the
MLH1 c.1276C > T and the MSH2 c.2152C > T were
identified in ≥7 families from different Brazilian cities
and the MLH1 c.665del was identified in 4 unrelated
Uruguayan families. Recurrent pathogenic variants
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Fig. 2 Type of MMR variants in Latin America LS families
Rossi et al. BMC Cancer  (2017) 17:623 Page 9 of 26include: the MLH1 c.350C > T, c.1852_1854del and the
c.2041G > A. More precisely, the MLH1 c.350C > T was
identified in 5 unrelated families from Uruguay and
Argentina, the MLH1 c.1852_1854del was detected in 6
unrelated families from Argentina, Brazil, El Salvador
and Mexico, and the MLH1 c.2041G > A was observed
in 7 unrelated families from Chile, Colombia and Brazil.
These variants may thus represent frequent MLH1 vari-
ants in South American population. Moreover, we found
a high incidence of intronic and not previously reported
MSH6 and PMS2 variants in Argentina (Table 3).
Founder variants
Here, we identified 16 international founder variants: 8
in MLH1,7 in MSH2 and 1 in MSH6 pathogenic variants
in 27 LS families [23, 34, 36, 59–74] (Table 4). Inter-
national founder pathogenic variants detected in >2 un-
related LS families included e.g. MLH1 c.545 + 3A > G
identified as an Italian founder pathogenic variant [75],
MSH2 c.388_389del as a Portuguese founder variant
identified in Argentina [69]. The MSH2 c.942 + 3A > T
was found in 2 unrelated Brazilian families and widely
described as a Newfoundland founder variant. It had
been identified in different populations and could be
considered as a world-wide MSH2 variant [26, 64]. The
MLH1 c.1039-8T_1558 + 896Tdup has been suggested
to represent a founder MMR variant in Colombia [23].
In line with the Portuguese influence in Brazil, the
MLH1 c.1897-?_2271 +?del encompassing exons 17 to
19 have been identified in 4 unrelated Brazilian families
[69, 70]. The MLH1 c.2044_2045del have been recently
described as a founder variant in Puerto Rico [34, 36]
and the MSH2 c.1077-?_1276 +?del as a Spanish founder
Alu-mediated rearrangement which have been identified
in Argentina, Uruguay and Brazil [67].Update of the MMR variants from the previous South
America LS study
Due to changes in InSIGHT classification of variants, 14
variants were altered for the MLH1 gene and 2 for the
MSH2 gene, relative to our previous classification in
Dominguez-Valentin et al. [32]. For MLH1, 3 previously
classified Class 5 variants were downgraded to Class 4,
while 4 previously classified Class 5 were moved to Class
3 and 3 previously classified Class 5 were moved to Class
1 (MLH1: c.1558 + 14G > A, c.1852_1853delinsGC,
c.1853A > C). Three MLH1 variants were updated in their
nomenclature. For MSH2 gene, two variants were updated
in their nomenclature (Table 3).
Differences between LS patients according to the
path_MMR gene
The clinicopathological characteristics evaluated were
similar between path_MLH1, path_MSH2, path_MSH6,
path_PMS2 and path_EPCAM carriers, except for the
mean age at CRC diagnosis for MLH1 (39.6 years) and
MSH2 carriers (41.5 years) (p ≤ 0.05) (Table 5). For
path_MLH1 carriers, we observed that the probands had
more family history of CRC (56.4%) than LS-associated
cancers (20.1%) and 97% fulfilled the AMSII criteria. LS
individuals with path_MSH2, path_MSH6 and
path_PMS2 were mostly females (63.5%, 90% and 77.8%
respectively). Path_MSH2 carriers fulfilled AMSII cri-
teria (100%) while path_MSH6 and path_PMS2 carriers
had more family history of CRC (30% and 75%, respect-
ively) than LS-associated cancers (10% and 25%, respect-
ively). Path_EPCAM carriers had a lower number for
each clinical characteristic (Table 5). Deviating distribu-
tions of the parameters discussed above for path_MSH6
and especially path_PMS2 carriers may have escaped sig-
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Fig. 3 Latin America MMR variants spectrum
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Tumors specimens from 83 individuals from Peru, 6
from Argentina, 61 from Bolivia, and 60 from Mexico
were analyzed either by IHC and MSI-testing, MSI-
testing only, or IHC only, respectively, (Table 6). Of
these, 69 (32.8%) were found to have MMR-deficient tu-
mors as determined by IHC or MSI analysis (Table 6).
The range of the mean age at diagnosis was 27–43 yearsTable 4 Founder mutations found in Latin America LS families
Gene Founder mutation Total number of LS families (refere
MLH1 c.306 + 5G > A 1 in Brazil [61]
MLH1 c.545 + 3A > G 2 in Brazil [75]
MLH1 c.1039-8T_1558 + 896Tdup 2 in Colombia [23]
MLH1 c.1558 + 1G > T 1 in Brazil [65]
MLH1 c.1732-?_1896 +?del 1 in Brazil [66, 72]
MLH1 c.1897-?_2271 +?del 4 in Brazil [70, 68]
MLH1 c.2044_2045del 2 in Puerto Rico [34, 36]
MLH1 c.2252_2253delAA 1 in Argentina [40]
MSH2 c.(?_-68)_1076 +?del 1 in Argentina[63, 71, 73]
MSH2 c.388_389del 2 in Argentina and 1 in Brazil [69]
MSH2 c.942 + 3A > T 2 in Brazil [64]
MSH2 c.1077-?_1276 +?del 1 in Argentina, 1 in Uruguay and 1
MSH2 c.1165C > T 1 in Colombia [62]
MSH2 c.1277-?_1386 +?del 1 in Brazil [60]
MSH2 c.2185_2192del7insCCCT 1 in Chile [20]
MSH6 c.2983G > T 1 in Brazil [74]
LS Lynch syndromefor CRC and 37–52 years for endometrial cancer in the
different registries. The prevalence of deficient MMR
protein expression (MLH1, MSH2, MSH6, PMS2)
among Peruvian, Argentinean and Mexican patients was
48%, 50% and 38%, respectively, with most cases having
absence of MLH1 protein (data available upon request).
Regardless of their MMR proficiency status (proficient
vs. deficient), patients had similar ages at CRC diagnosisnces) Origin (comments)
Spain
Italy
(no haplotype studies were performed)
Italy
Finland
Portugal (mutation with an estimated age of 283 years)
Puerto Rico
Italy (Northern region)
Italy and North America
Portugal
Newfoundland (considered a world-wide MSH2 variant)





Table 5 Clinicopathologic characterization of LS patients acording to the affected MMR gene
Clinical characteristics Path_MMR carriers p
valuePath_MLH1 Path_MSH2 Path_MSH6 Path_PMS2 Path_EPCAM
Age at CRC diagnosis (mean)* 37.5–41.7 (39.6)* 38.6–41.7 (41.5)* 31.2–43.9 (37.5) 38–58 (48) 38–65 (51.5)
Gender (n(%))
Female 39 (54.2) 40 (63.5) 9 (90) 7 (77.8) 1 (33.3)
Male 33 (45.8) 23 (36.5) 1 (10) 2 (22.2) 2 (66.7) 0.261
Family history of CRC (n(%))
Yes 53 (56.4) 35 (48.6) 3 (30) 3 (75) 2 (66.7)
No 41 (43.6) 37 (51.4) 7 (70) 1 (25) 1 (33.3) 0.449
Family history LS associated cancers (n(%))
Yes 27 (20.1) 18 (25) 1 (10) 1 (25) 2 (66.7)
No 107 (79.9) 54 (75) 9 (90) 3 (75) 1 (33.3) 0.135
AMSII/Bethesda criteria (n(%))
AMSII criteria 131(97) 72(100) 8 (100) 2 (66.7) 2 (66.7)
Bethesda 4 (3) 0 0 0 1 (33.3) na
Other criteria 0 0 0 1 (33.3)
*P ≤ 0.05; LS: Lynch syndrome; CRC: colorectal cancer; na: not applied; Path_MMR: Pathogenic (disease-causing) variant of an MMR gene; path_MLH1: pathogenic
variant of the MLH1 gene; path_MSH2: pathogenic variant of the MSH2 gene; path_MSH6: pathogenic variant of the MSH6 gene; path_PMS2: pathogenic variant
of the PMS2 gene; path_EPCAM: pathogenic variant of the EPCAM gene
The analysis was performed based on available information from Hospital de las Fuerzas Armadas, Uruguay (except for the gender); Clinicas Las Condes, Chile;
Hospital Italiano, Argentina; Hospital Espanol de Rosario, Argentina; Hospital de Clinicas, Brazil (except for family history of LS associated cancers) and Clinica del
Country, Colombia
Rossi et al. BMC Cancer  (2017) 17:623 Page 20 of 26and gender (Table 7). As shown in Table 7, family his-
tory of CRC was increased in MMR-deficient individuals
compared to MMR proficient (P ≤ 0.05). Interestingly,
AMSII criteria were more frequently fulfilled among
MMR deficient (42.4%) than MMR-proficient (10.9%) in-
dividuals and this difference was statistically significant
(P ≤ 0.05) (Table 7).
Compilation of IHC and MSI data from reports on Latin

















82 83 41(13.1) 52(9.0
Centro de Enfermedades
Neoplasicas
Oncovida (La Paz, Boliva)b








6 6 43.3(8.7) NA
Total 157 210
a: MMR deficiency analyzed based on IHC and/or MSI; b: MMR deficiency based on
mismatch-repair; CRC: colorectal cancer; SD: standard deviation; IHC: immunohistoc
microsatellite stableentries) revealed that 21% had MMR deficiency based on
IHC and/or MSI analysis (2.5%–60%). No information
was available for the mean age at CRC and endometrial
cancer diagnosis (Table 8). This data highlights the im-
portance of genetic testing for LS in these populations.
Family history
Since there are no premonitory signs of susceptibility to








non-deficient (%)AMSII Revised Bethesda
1) 22 60 40(48.2) 43(51.8)
46 0 3(4.9) 58(95.1)
2.02) 11 12 23(38.3) 37(61.7)
0 6 3(50.0) 3(50.0)
79 78 69(32.8) 141(67.2)
BAT-25 MSI marker; c: MMR deficiency based on IHC; NA: not applied; MMR:
hemistry; MSI: microsatellite instability; MSI-H: MSI-high; MSS:
Table 7 Comparison of MMR- deficient versus MMR- proficient
individuals from suspected Latin America LS families
Clinical characteristics MMR status p value
Deficient Proficient
Age at CRC diagnosis (mean + − SD) 42.47 36.3
Gender (n(%))
Male 27 (39.1) 36 (34.6)
Female 42 (60.9) 68 (65.4) 0.545637
Family history of CRC (n(%))
Yes 66 (98.5) 40 (87)
No 1 (1.5) 6 (13) 0.012333
Family history Lynch syndrome associated cancers (n(%))
Yes 14 (20.9) 6 (13)
No 53 (79.1) 40 (87) 0.282626
AMSII/Bethesda criteria (n(%))
AMSII 28 (42.4) 5 (10.9)
Bethesda 38 (57.6) 41 (89.1) 0.000314
*P ≤ 0.05; CRC colorectal cancer, MMR mismatch repair
Rossi et al. BMC Cancer  (2017) 17:623 Page 21 of 26identifying patients at risk in Brazil, Mexico, Peru and
Paraguay. Four published reports showed that 11.5%
(107/931) were selected as likely LS on the basis of a
positive family history (Table 9).
Discussion
Progress has been achieved throughout the past years re-
garding a better molecular and clinical characterization
of LS in Latin America, which is important for the sur-
veillance and management of high-risk patients and their
families [2].
Here, we present the first thorough LS investigation in
Latin America by taking into account 15 different coun-
tries. We found that germline genetic testing for LS is
already available in six of these countries (Argentina,
Brazil, Chile, Colombia, Uruguay and Puerto Rico).
Moreover, in three countries (Bolivia, Peru and Mexico),
where genetic testing is not yet implemented, tumor
analyses are already performed for identifying patients
most likely to carry a path_MMR variant.
According to our data, the contribution from the
different MMR genes is apparently slightly higher for
MLH1 and MSH2 and lower for MSH6 and PMS2
when comparing to the InSIGHT database and inter-
national reports. It is possible that this pattern re-
flects the recent inclusion of MSH6, PMS2 and
EPCAM in LS genetic testing in Latin America mo-
lecular diagnostic laboratories but could also reflect
population structure [32, 48, 76, 77]. Interestingly, the
clinicopathological features of path_MMR carriers de-
scribed in Latin America families are in accordance
with other studies, e.g. the AMSII criteria were ful-
filled by 64% of the path_MMR carriers [37, 77].This study revealed that the Latin America spectrum
of MMR variants is broad with a total of 220 different
variants, of which 80% are currently considered as pri-
vate, whereas 20% are deemed as recurrent. Our data
support evidence on a significant contribution from
large deletions/duplications in EPCAM and frameshift
variants in MLH1 and MSH2. Of the 220 MMR variants,
178 were already listed in the InSiGHT database or pre-
vious studies [78, 79], whereas 41 have not been previ-
ously reported in LS [80]. In addition, we observed that
MSH2 variants most frequently caused disease in Argen-
tinean LS families. Further studies are needed to eluci-
date the ancestral origin of MMR variants in this
population, which may increase the knowledge on the
inheritance of LS among affected Latin America individ-
uals [10, 14, 17, 40].
Differences in the spectrum of path_MMR variants be-
tween populations could be due to differences in the
sample size, clinical criteria, selection bias, as well as,
genetic ancestry of the individual populations. For in-
stance, Caribbean Hispanics have higher percentage of
African ancestry compared to Argentineans and
Uruguay nationals [36]. Puerto Ricans are an admixed
population of three ancestral populations, including
European, Africans and Taínos [36]. The South Ameri-
can population is ethnically mixed from American In-
dian, European, and other ancestries, but the
proportions may vary between countries. For instance,
European ancestry predominates in Uruguay and
Argentina, whereas Brazil includes a more heteroge-
neous population, which is the result of interethnic
crosses between the European colonizers (mainly Portu-
guese), African slaves, and the autochthonous Amerin-
dians [15]. The Peruvian population is a multi-ethnic
population with Amerindian (45%), Mestizo (37%), white
Spanish influence (15%), as well as other minority ethnic
groups, such as African-American, Japanese, and Chin-
ese (3%) [24]. In Chile, Colombia and Bolivia, Spanish
colonist and American Indian ancestry influence the
populations [20, 32].
It is well established that awareness of founder vari-
ants in a specific geographic area or population can be
very helpful in designing cost-effective molecular diag-
nostic approaches [70, 81, 82]. Founder mutations pro-
vide molecular diagnostic centers the benefit of
unambiguous results and thereby, do not demand high
skilled professional training.
The other aim of the study was to investigate if the
previously MMR variants identified in South American
LS families [32] are in accordance with the 5-tier classifi-
cation system [55]. We were able to refine the classifica-
tion of 16 MLH1 and MSH2 variants.
When the tumor MMR data from original and pub-
lished studies were combined, up to 33% of suspected
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(0.6)
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MMR mismatch repair, MSI microsatellite instabily, MSI-H MSI-high, MSS microsatellite stable; na not applied, SD standard deviation, IHC immunohistochemistry
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MMR deficiency was lower than that reported in studies
focusing in American, Spanish and Australian LS fam-
ilies (56%–72%) but is in line to the reported prevalence
of MSI in sporadic CRC among Hispanic patients [34,
83–86]. These differences could also be a reflect of the
differences in the tumor testing methodologies across
the countries, e.g. MSI analysis is not widely available in









Mexico City, Mexico [49] 210 210 2 0
Asuncion, Paraguay [50] 324 324 9 0
Sao Paulo, Brazil [19] 311 311 4 41
Lima, Peru [33] 86 86 20 31
Total 931 931 35 72
na not applied, MMR mismatch-repair genes, CRC colorectal cancer, LS Lynch syndrothe number of MSI mononucleotide markers varies be-
tween laboratories as well as the limitation in the num-
ber of MMR proteins analyzed by IHC. Moreover, even
if MMR deficiency is a good predictor of carrying a
germline path_MMR variant, MMR deficiency can also
result from somatic inactivation, most commonly due to
methylation of the MLH1 promoter [86]. IHC and MSI
testing will, however, combined identify most LS patients













56 154 2 (0.95) 208 (99.05) na
na 315 9 (2.8) 315 (97.2) 55
213 98 45 (31.5) 266 (85.5) na
80 6 51 (59.3) 35 (40.7) na
349 573 107 (11.5) 824 (88.6)
me
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grating genetics into clinical practice a challenge, a situ-
ation in which the use of family history becomes
important for patient care, as it is a low-cost strategy
and a risk assessment tool [19]. In this scenario, pub-
lished family history data from Paraguay, Peru, Brazil
and Mexico suggest its use as a triage tool together with
IHC and MSI to identify and stratify genetic risk in these
populations [19]. However, awareness of hereditary can-
cer among clinicians involved in diagnosis and treatment
of CRC is currently low, and families actually meeting
the clinical criteria may not be identified [77]. In
addition, the average life expectancy in Latin America
and the Caribbean is 75 years and inequalities persist
among and within the countries (www.paho.org). These
countries are mainly represented by a young population
where family history could be less informative and in-
sensitive for assessing genetic screening for LS.
Limitation on genetic testing has an impact in the evalu-
ation of the patients at risk of hereditary cancer and their
relatives, and ultimately increases the burden of cancer for
this minority population [35]. As mentioned, in Latin
America, genetic testing is not routinely available at the
public health system, with exception of few studies con-
ducted in research institutes or private institutions. For in-
stance, until recently the coverage of oncogenetic services
in Brazil, was restricted to less than 5% of the population.
However, a significant advance took place in 2012, when
the coverage of genetic testing by private health care plans
became mandatory in Brazil, currently covering around
20–30% of the population [19, 87].
This work provides a snapshot view of the current LS-
associated diagnostics practice/output in Latin America.
The limitations of this study include the selection of pa-
tients recruited from selected reference centers and/or
from a nation-wide public reference hospital for cancer
patients that cannot renders a representative sample.
Furthermore, the diagnostic methodologies may vary be-
tween the countries regarding the coverage of the coding
region of the genes tested and the clinical criteria for re-
ferral to genetic counseling and testing, thus causing an
even larger knowledge gap. Finally, several countries are
not represented; for instance, we could not find any re-
ports from Venezuela, Honduras, Nicaragua or Ecuador.
It will be important to pursue additional studies on LS
in Latin America countries to both increase the know-
ledge of MMR variants in different populations and to
bring additional awareness of this condition to medical
professionals and public health leaders in Latin America.
Conclusions
The Latin America LS MMR variants spectrum included
new MMR variants, genetic frequent regions and poten-
tial founder effect. The present study provides supportto set or improve LS genetic testing in these countries.
Improving the accessibility, including tertiary care, is
vital in low-income and middle-income countries that
face an increasing burden of CRC. An early diagnosis
and intensive screening may predict the disease and/or
improve the disease prognosis. Low cost approaches to
reach these ends are discussed.
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